The Rich Heterogeneity of Platelets and Its Vital Shifts Across Disease States – RPTH
Research and Practice in Thrombosis and Haemostasis (RPTH) shared a post on LinkedIn about a recent article by Deepa Gautam, adding:
“Are all platelets the same?
Or are we missing critical biology hiding in plain sight?
We still rely on platelet count and MPV in both research and the clinic.
But this study shows that platelets are far from uniform and that heterogeneity systematically shifts across disease states.
Here’s what this paper delivers.
Using a 12-marker spectral flow cytometry panel pus high – dimensional clustering (PlateletProfiler), the authors map platelet states at single – cell resolution.
Platelets exist along an activation continuum, not just ‘resting vs activated’:
- Resting
- Primed
- Aggregatory
- Procoagulant
Disease reshapes platelet composition across models:
- Inflammation (LPS) – expansion of primed plus aggregatory platelets
- Jak2V617F (MPN) – increase in aggregatory plus procoagulant platelets
- Cancer – enrichment of procoagulant platelets
Key mechanistic signal, all models showed:
- Increased reticulated (young) platelets
- Upregulation of activation plus immune markers (e.g., PD-L1, CD154)
This suggests:
- Accelerated thrombopoiesis
- Functionally ‘pre-activated’ circulating platelets
- A link between platelet biology and immune modulation
Why this matters
We’ve been treating platelets as a homogeneous population.
This framework opens the door to:
- Subpopulation-specific biomarkers
- More precise antiplatelet strategies
- Better mechanistic links between platelets, inflammation, and cancer”
Title: Characterizing mouse platelet heterogeneity across diverse disease models using spectral flow cytometry and high-dimensional analysis
Authors: Deepa Gautam, Emily M. Clarke, Rebecca L. Zon, Margaret R. Smith-Oliver, Avinash Kumar 5, Megan E. Sullivan, Panagiotis Karagiannis, Harvey G. Roweth, Elisabeth Battinelli
Read the Full Article on RPTH
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 11, 2026, 13:51David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene
-
Apr 11, 2026, 13:47Samrawit Terefe: O Negative Blood Is the Universal Donor With Extreme Scarcity
-
Apr 11, 2026, 13:39Dheeraj Garg: Rethinking Cardiovascular Disease – A Cardiologist’s Perspective
-
Apr 11, 2026, 13:37Kushal Bhatia: Is The 4.5-Hour Thrombolysis Window Officially Outdated?
-
Apr 11, 2026, 13:35William Aird: Why Did Mammalian Red Blood Cells Give Up Their Nucleus?
-
Apr 11, 2026, 13:30Ken Kuang: Gravity Is Constant, But Your Vein Health Doesn’t Have to Be
-
Apr 11, 2026, 13:21Mascha Kern: Measuring Gender’s Role in Stroke and Migraine
-
Apr 11, 2026, 13:10Danique Steeghs: Key Findings from a Microfluidic Chemiluminescent Thrombin Generation Assay
-
Apr 11, 2026, 13:06Shanvi Mahi: A Validated Tool to Explore Lived Experiences After Stroke Rehabilitation